Journal of Critical Care
Volume 23, Issue 4 , Pages 500-506 , December 2008

Effect of corticosteroids on arginine vasopressin–containing vasopressor therapy for septic shock: a case control study

  • Seth R. Bauer, PharmD, BCPS

      Affiliations

    • Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio
    • Corresponding Author InformationCorresponding author. Department of Pharmacy, Cleveland Clinic (Mail Code JJN1-02), Cleveland, OH 44195, USA.
    • ,
  • Simon W. Lam, PharmD

      Affiliations

    • Department of Pharmacy, NewYork-Presbyterian Hospital, Columbia University Medical Center, New York, New York
    • ,
  • Stephen S. Cha, MS

      Affiliations

    • Division of Biostatistics, Mayo Clinic, Rochester, Minnesota
    • ,
  • Lance J. Oyen, PharmD, BCPS, FCCM

      Affiliations

    • Department of Pharmacy, Mayo Clinic, Rochester, Minnesota

References 

  1. Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34:344–353
  2. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368–1377
  3. Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med. 1998;26:645–650
  4. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double blind, single center study. Crit Care Med. 1999;27:723–732
  5. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low dose hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288:862–871
  6. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358:111–124
  7. Oppert M, Schindler R, Husung C, et al. Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med. 2005;33:2457–2464
  8. Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ. 2004;329:480
  9. Keh D, Boehnke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of “low dose” hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med. 2003;167:512–520
  10. Annane D, Bellissant E, Sebille V, et al. Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. Br J Clin Pharmacol. 1998;46:589–597
  11. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36:296–327
  12. Patel BM, Chittock DR, Russell JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology. 2002;96:576–582
  13. Malay MB, Ashton RC, Landry DW, et al. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma. 1999;47:699–703
  14. Dünser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation. 2003;107:2313–2319
  15. Hall LG, Oyen LJ, Taner CB, et al. Fixed-dose vasopressin compared with titrated dopamine and norepinephrine as initial vasopressor therapy for septic shock. Pharmacotherapy. 2004;24:1002–1012
  16. Karmazyn M, Manku MS, Horrobin DF. Changes of vascular reactivity induced by low vasopressin concentrations: interactions with cortisol and lithium and possible involvement of prostaglandins. Endocrinology. 1978;102:1230–1236
  17. Holmes CL, Patel BM, Russell JA, et al. Physiology of vasopressin relevant to management of septic shock. Chest. 2001;120:989–1002
  18. Mutlu GM, Factor P. Role of vasopressin in the management of septic shock. Intensive Care Med. 2004;30:1276–1291
  19. Chant C. Endocrine interventions in the critically ill patient. In:  Schumock G,  Brundage D,  Richardson M, et al. editor. Pharmacotherapy Self-Assessment Program, 5th ed. Critical care and transplantation. Kansas City: American College of Clinical Pharmacy; 2006;p. 21–45
  20. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101:1644–1655
  21. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–829
  22. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996;22:707–710
  23. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709
  24. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based in European/North American multicenter study. JAMA. 1994;270:2957–2963
  25. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med. 2001;345:588–595
  26. Barrett LK, Singer M, Clapp LH. Vasopressin: mechanism of action on the vasculature in health and in septic shock. Crit Care Med. 2007;35:33–40
  27. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358:877–887
  28. Sharshar T, Blanchard A, Paillard M, et al. Circulating vasopressin levels in septic shock. Crit Care Med. 2003;31:1752–1758
  29. Ullian ME. The role of corticosteroids in the regulation of vascular tone. Cardiovasc Res. 1999;41:55–64
  30. Annane D, Sebille V, Troche G, et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA. 2000;283:1038–1045
  31. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858–873

☆ This study was performed at Mayo Clinic, Rochester, Minn.

☆☆ Supported by departmental funding of the Department of Pharmacy Services, Mayo Clinic, Rochester, Minn.

PII: S0883-9441(08)00104-4

doi: 10.1016/j.jcrc.2008.04.002

Journal of Critical Care
Volume 23, Issue 4 , Pages 500-506 , December 2008

Article Tools

* Image Usage & Resolution